10:12 AM EDT, 05/03/2024 (MT Newswires) -- Catalent ( CTLT ) said Friday the US Federal Trade Commission is asking for more information while the agency reviews the proposed acquisition of the biologics and gene therapies company by Danish drug maker Novo Nordisk ( NVO ) .

The ongoing antitrust review is expected to add another 30 days to the regulatory process, unless extended or terminated sooner by the FTC, the companies said, adding they were currently working to gather all of the requested information.

The proposed $16.5 billion transaction is expected to close by the end of 2024, subject to the successful completion of FTC and other regulatory examinations along with other customary conditions.

Catalent ( CTLT ) shares were up 0.02% in recent Friday trading, while Novo Nordisk's ( NVO ) shares were recently falling nearly 2%.

Price: 56.35, Change: +0.01, Percent Change: +0.02